90% of Life Sciences Manufacturers Say Digital Transformation Is Now Business-Critical, According to New Rockwell Automation Report

What happened

Rockwell Automation has published a new report finding that 90% of life sciences manufacturers now regard digital transformation as business-critical rather than optional. The finding, reported via PR Newswire and picked up by TradingView, signals a shift in how pharmaceutical, biotech and medical device manufacturers view technology investment — from a modernisation nice-to-have to a core strategic priority.

The coverage does not detail the survey's full methodology, sample size or regional breakdown, but the headline figure positions digital transformation as a near-universal priority across the sector, reflecting pressure on manufacturers to modernise operations, data systems and production processes.

Why it matters

For a sector historically cautious about technology change — given the regulatory scrutiny, validation requirements and quality-control stakes involved in manufacturing medicines and devices — a 90% figure indicates that digital transformation has moved from the innovation lab to the boardroom agenda. When nine in ten manufacturers converge on the same view, it suggests the debate within life sciences has shifted from whether to invest in automation, data and connected operations to how quickly and how well that investment can be executed.

This matters for digital transformation leaders because life sciences has tended to lag other industrial sectors in adopting cloud, automation and real-time data infrastructure, partly due to compliance complexity. A sector-wide consensus of this scale suggests the barriers being weighed are shifting from "should we" to execution risk, talent and integration with legacy validated systems.

The Renascence take

Surveys like this are useful as a temperature check, but the real story is rarely the headline percentage — it's the gap between stated intent and operational follow-through. Regulated manufacturing environments are notoriously slow to turn strategic consensus into working systems, because validation cycles and quality frameworks don't move at software speed.

Nine in ten executives agreeing that transformation is "business-critical" tells us almost nothing about readiness — it tells us the narrative has won, not the execution. The behavioral risk here is consensus theatre: once an idea becomes socially unacceptable to disagree with internally, investment decisions get rubber-stamped faster than the underlying operating model, workforce skills or data architecture can actually support. A genuinely customer- and patient-obsessed manufacturer should treat this statistic as a prompt to audit where transformation is real versus declared — starting with how shop-floor data actually flows into decisions, not how it appears in a strategy deck.